Thillai K, Sarker D, Ross P. Progress in pancreatic cancer therapeutics: The potential to exploit molecular targets. World J Pharmacol 2015; 4(2): 180-192 [DOI: 10.5497/wjp.v4.i2.180]
Corresponding Author of This Article
Dr. Paul Ross, Department of Medical Oncology, Guy’s and St Thomas NHS Trust, Great Maze Pond, SE19RT London, United Kingdom. paul.ross@gstt.nhs.uk
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Pharmacol. Jun 9, 2015; 4(2): 180-192 Published online Jun 9, 2015. doi: 10.5497/wjp.v4.i2.180
Progress in pancreatic cancer therapeutics: The potential to exploit molecular targets
Kiruthikah Thillai, Debashis Sarker, Paul Ross
Kiruthikah Thillai, Debashis Sarker, Paul Ross, Department of Medical Oncology, Guy’s and St Thomas NHS Trust, SE19RT London, United Kingdom
Author contributions: All authors contributed to this manuscript.
Conflict-of-interest: The authors declare no conflict of interest relevant to this article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Paul Ross, Department of Medical Oncology, Guy’s and St Thomas NHS Trust, Great Maze Pond, SE19RT London, United Kingdom. paul.ross@gstt.nhs.uk
Telephone: +44-207-1887188 Fax: +44-207-1887534
Received: December 2, 2014 Peer-review started: December 2, 2014 First decision: February 7, 2015 Revised: March 9, 2015 Accepted: April 10, 2015 Article in press: April 14, 2015 Published online: June 9, 2015
Core Tip
Core tip: Pancreatic ductal adenocarcinoma is a cancer with several significant genetic aberrations that have recently been identified by international research efforts. Despite these findings, standard therapy for advanced disease consists primarily of chemotherapy. In the last few years two new chemotherapy regimens, FOLFIRINOX and Gemcitabine/Nab-paclitaxel, have demonstrated survival benefits in large phase III trials resulting in a change to current practise. However, the advent of targeted treatments has not yet had a significant impact in this disease compared with other malignancies. Current research strategies include developing therapies directed towards the RAS-RAK-MEK pathway, PI3K-AKT-mTOR pathway, notch pathway and immunotherapies to name but a few, with several clinical trials underway. It is likely that the heterogeneous nature of pancreatic cancer necessitates a more personalised approach to management with targeted treatment guided by predictive biomarkers.
